PLL001
/ PLL Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 25, 2025
A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients
(clinicaltrials.gov)
- P1/2 | N=153 | Recruiting | Sponsor: PLL TX AUSTRALIA PTY LTD | Not yet recruiting ➔ Recruiting
Enrollment open • Amyotrophic Lateral Sclerosis • CNS Disorders
July 22, 2024
A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo Controlled Study With an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001 for the Treatment of Subjects With Amyotrophic Lateral Sclerosis
(clinicaltrials.gov)
- P1/2 | N=153 | Not yet recruiting | Sponsor: PLL TX AUSTRALIA PTY LTD
New P1/2 trial • Amyotrophic Lateral Sclerosis • CNS Disorders
1 to 2
Of
2
Go to page
1